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Our current understanding of the pathogenesis of cystic fibrosis (CF) lung disease stresses the
importance of the physical and chemical properties of the airway surface liquid (ASL). In
particular, the loss of cystic fibrosis transmembrane conductance regulator (CFTR) chloride
channel function in CF reduces the volume and fluidity of the ASL, thus impairing muco-
ciliary clearance and innate antimicrobial mechanisms. Besides direct approaches to restor-
ing mutant CFTR function, alternative therapeutic strategies may also be considered to
correct the basic defect of impaired salt and water transport. Such alternative strategies are
focused on the restoration of mucociliary transport by (1) reducing sodium and fluid absorp-
tion by inhibiting the ENaC channel; (2) activating alternative chloride channels; and (3)
increasing airway surface hydration with osmotic agents. Therapeutic approaches directed at
targets other than CFTR are attractive because they are potentially useful to all patients
irrespective of their genotype. Clinical trials are underway to test the efficacy of these ap-
proaches.
The study of the normal physiologic processesthat contribute to innate lung defenses has
allowed the identification of important defects
involved in the pathogenesis of cystic fibrosis
(CF) lung disease. There is substantial evidence
that mucociliary clearance is perhaps the most
important initial line of lung defense and that
defective mucociliary clearance is responsible
for the development and progression of the
chronic lung disease that typifies CF. It is impor-
tant, therefore, to review the elements that com-
pose the mucus-clearance apparatus.
In the last 30 years, a series of studies revealed
the importance of the airway-lining fluid for
defense against microbial pathogens. This air-
way-surface liquid layer (ASL) is composed of
two layers: a periciliary layer (PCL), containing
water, low-molecular-weight ions, and a com-
plex collection of secreted and cell-surface-
tethered proteins; and an overlying mucus layer,
primarily composed of secreted mucins. Act-
ing in concert with secreted antimicrobial sub-
stances (e.g., lysozyme, lactoferrin, and defen-
sins), the mucus layer efficiently traps and clears
inhaled pathogens and particulates. The PCL, in
turn, provides a lubricant layer, in which cilia
can beat freely to propel the mucus layer toward
the mouth. Proper regulation of ASL volume,
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therefore, facilitates cilia motion and ensures
adequate hydration of its component layers.
Both attributes are critical to the maintenance
of mucus clearance.
Although fluid may be donated to the ASL
compartment via the distal lung compartment
and submucosal glands, the superficial epithelia
play a key role in regulating ASL volume through
its capacity to initiate both liquid absorption
and secretion. The absorption of ASL is accom-
plished via active sodium transport, with the
apical epithelial sodium channel (ENaC) medi-
ating the rate-limiting step in this process. Liq-
uid secretion across the superficial epithelium is
conducted through cystic fibrosis transmem-
brane conductance regulator (CFTR) and calci-
um-activated chloride channels (CaCC). CFTR
appears to play a central role in this process: it is
the primary pathway for chloride secretion un-
der basal conditions, and it also regulates the
activity of ENaC via mechanisms that are still
being elucidated. By regulating liquid absorp-
tion and secretion, CFTR ensures that the PCL
remains at least 7 mm thick (approximating the
height of cilia) and that the mucus layer is ade-
quately hydrated for transport.
The importance of CFTR as a homeostatic
regulator of ASL volume is demonstrated by the
severe consequences observed in CF patients. CF
epithelia hyperabsorb liquid because of dysregu-
lation of ENaC and the absence of capacity to
secrete liquid through CFTR (Stutts et al. 1995).
As demonstrated by studies using primary cell
cultures, these ion-transport abnormalities re-
sult in an abnormally shallow PCL, which in
turn causes spontaneous mucus transport to
stop (Matsui et al. 1998). Though it is certain
that chloride secretion through CaCC can par-
tially compensate for the loss of CFTR (Tarran
et al. 2002), the system is vulnerable to insults
(e.g., viral infection) that, over time, result in the
accumulation of poorly clearing lung regions
and mucus obstruction (Tarran et al. 2005).
ASL dehydration and impaired mucus transport
are believed to create a favorable environment
for the initial acquisition and subsequent prolif-
eration of bacteria in the airways. Developing
therapies that correct these ion-transport abnor-
malities, therefore, may provide the means to
prevent or delay the onset and progression of
CF lung disease.
TARGETING CFTR
Over the past decade, many efforts have been
aimed at developing strategies to recover mutant
CFTR function. In this respect, it must be con-
sidered that CF mutations cause loss of CFTR
function by different mechanisms, including
impaired exit of the protein from the endoplas-
mic reticulum and/or defective channel gating.
Therefore, CFTR-directed therapies must be
tailored to specific mutations, or groups of mu-
tations, sharing the same type of functional de-
fect. For example, pharmacological agents called
potentiators, able to stimulate CFTR channel
opening, have been developed to treat patients
carrying mutations that impair CFTR gating,
such as G551D. The potentiator VX-770 (Vertex
Pharmaceuticals) has been tested in phase II and
III clinical trials with positive results (Accurso
et al. 2010). Pharmacological correctors, aimed
at the rescue of mutant CFTR (e.g., DF508-
CFTR) from the endoplasmic reticulum and en-
couraging ribosomal read-through of abnormal
stop mutations, are also undergoing clinical tri-
als, as are combinations of correctors and po-
tentiators. The approaches used to target CFTR
directly are covered much more extensively else-
where.
Whereas targeting CFTR might be the most
rational and effective approach to fully restoring
ion transport in CF, therapeutics aimed at dif-
ferent targets are also under active investigation.
Although indirect, this approach has potential
advantages when compared to CFTR-directed
therapies. First, this approach utilizes receptors
and ion channels that are known to be expressed
at appropriate cellular locations and, therefore,
do not require us to replace or restore CFTR at
the apical membrane. Second, effective restora-
tion of airway surface hydration by targeting
proteins other than CFTR is expected to be ben-
eficial for all CF patients, irrespective of their
type of mutation. Fortunately, a number of po-
tential therapeutic targets are available, which
provide significant hope for developing novel,
effective treatments for CF lung disease (Fig. 1).
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Figure 1. Three alternative strategies to correct the intrinsic airway surface liquid defect (ASL) in cystic fibrosis.
(Top) Inhibition of sodium absorption through ENaC may be obtained by direct inhibition of the channel (e.g.,
with amiloride or analogs) or by preventing its activation mediated by proteases. (Middle) Stimulation of
calcium-activated chloride channels (CaCCs) by direct activators (openers) or by inducing intracellular calcium
elevation through a surface receptor (e.g., the purinergic P2Y2 receptor) is another potential way to promote
ASL normalization in CF. (Bottom) Improved hydration of airway surfaces can be obtained by aerosolized
osmolytes (e.g., hypertonic saline or mannitol).
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One of the possible therapeutic targets outside
of CFTR is ENaC. Sodium hyperabsorption
through ENaC has been described as a primary
pathophysiologic feature of CF epithelia. The
data supporting this conclusion come from a
variety of in vitro and in vivo systems, includ-
ing nasal and lower-airway potential-difference
measurements (Knowles et al. 1981) and short-
circuit current measurements in excised and cul-
tured tissues (Willumsen and Boucher 1991).
Following these observations, a mouse model
was created that, with overexpressed b-subunit
of ENaC in its airways, was used to test the
hypothesis that sodium hyperabsorption was
sufficient to cause a CF-like lung disease (Mall
et al. 2004). Indeed, these mice developed PCL
depletion and mucus obstruction. Similarly, de-
letion of Nedd4 L, a ubiquitin ligase involved in
down-regulation of ENaC, also led to the devel-
opment of Naþ hyperabsorption and a CF-like
lung phenotype (Kimura et al. 2011). Identifi-
cation of the mechanism(s) underlying sodium
hyperabsorption in CF, however, has been a dif-
ficult and sometimes contentious problem. Re-
cently, it appears that CFTR expression (wild
type, but not DF508) prevents proteolytic acti-
vation of the a- and g-ENaC subunits by en-
dogenous proteases involved in the normal reg-
ulation of this channel (Gentzsch et al. 2010).
Because ENaC and CFTR coimmunoprecipi-
tate, this relationship could result from a direct
physical association or from the formation of a
regulatory complex. Additional disruption of
ENaC regulation by endogenous proteases may
come from changes in the ASL environment it-
self in CF (Myerburg et al. 2006; Tarran et al.
2006). It has been shown that ENaC activity re-
sponds to changes in the volume and/or com-
position of the overlying ASL (Myerburg et al.
2010). Dilution of the thin lining fluid on air-
ways leads to a rapid upregulation of ENaC
activity, whereas progressive ASL absorption is
normally associated with reduced ENaC activi-
ty. It has become increasingly clear that, in CF,
the balance between serine protease and anti-
protease activity is disrupted, causing full pro-
teolytic activation of ENaC, even under low ASL
volume conditions where down-regulation of
ENaC activity would be expected and desirable.
Although altered levels of protease and anti-
protease activities could account for these find-
ings, other factors may also be involved. For
example, SPLUNC1—a highly expressed, se-
creted protein—was found to bind to ENaC
and protect it from proteolytic cleavage/activa-
tion (Garcia-Caballero et al. 2009; Rollins et al.
2010). While not possessing intrinsic antipro-
tease activity itself, alterations in the expression
or binding of SPLUNC to ENaC could also re-
sult in constitutive activation of ENaC by en-
dogenous proteases.
The evidence that sodium hyperabsorp-
tion contributes to ASL volume depletion in CF
makes ENaC activity an attractive therapeutic
target. Most simply, this could be accomplish-
ed through the use of inhaled ENaC blockers,
such as amiloride (Knowles et al. 1990). The
major challenge facing this approach is achiev-
ing the desired drug effectiveness and durability
in the lung while avoiding systemic exposure
that could lead to unwanted renal effects (i.e.,
hyperkalemia) (Knowles et al. 1992). One po-
tential criticism of this therapeutic approach is
that while slowing sodium/volume absorption
might be desirable in CF, if adequate chloride/
volume secretion does not accompany it, the
desired improvements in ASL hydration and
mucociliary clearance (MCC) might not be
achieved. The combination of an ENaC inhibi-
tor with a secretagogue (e.g., a hyperosmotic
agent or CaCC stimulator), therefore, might
be more beneficial.
A second approach to preventing sodium
hyperabsorption is to block proteolytic activa-
tion of ENaC, which appears to be dysregulated
in CF airways (Tarran et al. 2006; Myerburg et al.
2008). Peptide and small molecule inhibitors of
relevant proteases have been proposed for this
purpose, with supportive data from in vitro and
animal studies (Bridges et al. 2001; Coote et al.
2009). However, testing the safety and efficacy of
this approach in humans has yet to be accom-
plished. This approach is complicated by the
fact that multiple endogenous proteases appear
to be able to activate ENaC (e.g., prostasin,
TMPRSS4, matriptase) under normal condi-
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tions (Donaldson et al. 2002; Vuagniaux et al.
2002; Garcia-Caballero et al. 2008), and activa-
tion by neutrophil elastase in the highly in-
flamed CF airway is also possible (Caldwell
et al. 2005). It is likely that a broad-spectrum
antiprotease, or knowledge that selective inacti-
vation of a key protease in a signaling cascade
would be effective, will be needed. Alternative-
ly, given the recent data that CFTR and/or
SPLUNC shield ENaC from proteolysis by sev-
eral proteases expressed in cell culture systems, a
therapeutic approach that leverages this knowl-
edge could be conceived of as well.
CLINICAL STUDIES OF ENaC INHIBITORS
Clinical studies of inhaled amiloride, the proto-
type channel blocker, showed acute improve-
ments in mucociliary clearance (Kohler et al.
1986) but little to no improvement in lung func-
tion or other clinically meaningful parameters
(Knowles et al. 1990; Graham et al. 1993). Be-
cause amiloride has a short half-life in airways,
likely limiting its efficacy, efforts have been
made to develop more potent and longer-acting
analogs. One blocker, PS552-02 (Parion Sci-
ences), has entered phase II trials in CF (Hirsh
et al. 2008). This compound is roughly 60-fold
more potent than amiloride at blocking ENaC
currents in cultured human airway cells, and it
has also demonstrated a significantly increased
ability to stimulate MCC in a sheep model. Im-
portantly, whereas the effect of amiloride had
waned by 4 h postdose in this model, PS552-
02 continued to demonstrate an effect on clear-
ance. Similar effects on MCC were demonstrat-
ed in healthy human volunteers (Donaldson
et al. 2005), and preliminary reports of a multi-
dose study in CF subjects did not reveal major
safety concerns. Whether the regular use of this
or other ENaC inhibitors currently being devel-
oped results in clinically important outcomes
has not yet been demonstrated.
The concept that agents from different drug
classes (e.g., osmotic agent or P2Y2 agonist with
an ENaC blocker) might yield additive or syner-
gistic results is quite appealing. Although attrac-
tive, these approaches will require careful clini-
cal testing. Interestingly, the combination of
amiloride and hypertonic saline (HS) did not
yield any additional improvements over HS
alone, and in fact appeared to inhibit the bene-
ficial effects of HS on MCC and lung function
(Donaldson et al. 2006). Subsequent in vitro
experiments suggested that off-target effects of
amiloride in CF epithelia (i.e., reductions in
osmotically driven water transport) may have
prevented the expected ASL volume responses
to HS that would lead to augmented MCC im-
provements. Similar in vitro studies with PS552-
02 have not shown evidence of comparable off-
target activities, and indeed pretreatment before
HS administration increases the peak ASL vol-
ume response and extends the duration of ASL
volume expansion (Hirsh et al. 2008). We await
clinical trials to further test the concept that
combination therapy may be useful in CF.
TARGETING ALTERNATIVE CHLORIDE
CHANNELS
The molecular identity of CaCC has remained
elusive for many years (Galietta 2009). Howev-
er, three independent studies in 2008 identified
TMEM16A, also known as anoctamin-1, as a
membrane protein responsible for CaCC activ-
ity (Caputo et al. 2008; Schroeder et al. 2008;
Yang et al. 2008). Expression of TMEM16A
by transfection in null cells (i.e., devoid of
endogenous activity of CaCCs) causes the ap-
pearance of CaCC-like membrane currents.
Conversely, silencing TMEM16A expression in
airway epithelial cells via RNA interference
causes significant inhibition of calcium-depen-
dent chloride secretion. These observations in-
dicate that TMEM16A is an important compo-
nent of CaCCs.
However, there are still several unanswer-
ed questions. First, it is not clear whether
TMEM16A is directly activated by calcium or
if another protein, such as calmodulin, repre-
sents the “calcium sensor” (Tian et al. 2011). It
is also possible that activation by calcium in-
volves a phosphorylation event, as indicated by
some studies (Wagner et al. 1991; Xie et al.
1996). In other cases, phosphorylation seems
to have an inhibitory role, leaving this issue un-
resolved (Wang and Kotlikoff 1997; Greenwood
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et al. 2001). Obviously, elucidation of CaCC reg-
ulation mechanisms is important if we are to
devise pharmacological strategies that lead to
stimulation of alternative chloride transport in
CF cells. The recent identification of TMEM16A
may help our understanding of the molecular
mechanisms affecting CaCC function.
The TMEM16A discovery also opens the
possibility of finding pharmacological activa-
tors that can directly open CaCC channels with-
out altering cytosolic calcium. For this purpose,
TMEM16A-expressing cells could be utilized in
high-throughput screenings of large chemical
libraries, as has been done to identify activators
and inhibitors of the CFTR channel (Verkman
and Galietta 2009). However, it is important to
note that a recent study has questioned the role
of TMEM16A as a CaCC protein in airway
epithelia. According to this study, a selective
TMEM16A inhibitor was able to strongly block
calcium-dependent chloride secretion in sali-
vary glands but had minor effects on bronchial
epithelial cells (Namkung et al. 2011). This find-
ing would suggest that another protein, not
TMEM16A, is responsible for CaCC activity in
airway epithelial cells. But this conclusion con-
trasts with the findings of other studies. For
example, silencing TMEM16A in human bron-
chial epithelial cells caused a significant de-
crease in calcium-dependent chloride secretion
(Caputo et al. 2008). Furthermore, chloride se-
cretion and MCC were also significantly de-
creased in TMEM16A knockout mice (Ousing-
sawat et al. 2009; Rock et al. 2009). Additional
studies are required to resolve these controver-
sial findings.
Despite lacking knowledge of the molecular
identify of CaCC, early studies indicated that
airway epithelia possessed a chloride secretory
pathway other than CFTR (Anderson and Welsh
1991; Mason et al. 1991). In these studies, in-
creases in cytosolic calcium by different ago-
nists caused the activation of chloride channels
with biophysical and pharmacological proper-
ties distinct from those of CFTR. Experiments
in CF epithelia provided the most conclusive
demonstration that CaCCs and CFTR represent
separate entities (Anderson and Welsh 1991;
Knowles et al. 1991; Mason et al. 1991). Such
cells had CaCC-dependent membrane currents
but no cAMP-activated chloride transport. In
vitro measurements of the PCL height with a
confocal microscope also demonstrated that
CaCCs have the ability to influence airway sur-
face hydration (Tarran et al. 2005). Stimulation
of these channels by calcium agonists evokes a
transient increase in PCL thickness and im-
provement in mucociliary transport in both
normal and CF epithelia. This is a clear indi-
cation that stimulation of alternative chloride
channels may, at least in part, compensate the
CFTR defect.
How CaCC compensates for the lack of
functional CFTR in CF is not completely estab-
lished. In fact, it is not clear whether these two
channels have fully overlapping physiological
functions. In this respect, it has been shown
that CFTR transports anions other than chlo-
ride that may have crucial physiological func-
tions. For example, secretion of bicarbonate
through CFTR (Smith and Welsh 1992; Illek
et al. 1997) could be important in the expansion
of mucins following exocytosis (Garcia et al.
2009) and in the regulation of PCL pH (Coakley
et al. 2003). CFTR activity has also been directly
linked to an antimicrobial function. Indeed,
CFTR is permeable to thiocyanate, a physiolog-
ical anion that is actively transported through
the basolateral membrane by a sodium-coupled
mechanism (Fragoso et al. 2004). When secret-
ed onto the apical surface of the epithelium,
thiocyanate is converted to hypothiocyanite by
lactoperoxidase, an enzyme that also consumes
hydrogen peroxide as the second substrate (Ger-
son et al. 2000). Hypothiocyanite has been
reported to be an effective bactericidal mole-
cule. Therefore, impaired thiocyanate transport
through CFTR could generate a deficit in an
important innate defense mechanism (Conner
et al. 2007; Moskwa et al. 2007). Reassuringly,
activation of CaCCs could provide a route not
only for chloride secretion, but also for HCO3
2
and SCN2 transport. However, consideration of
CaCC as a suitable drug target to circumvent the
CFTR defect requires a better understanding of
CaCC structure, regulation, and function.
In the absence of direct CaCC activators,
strategies aiming at the stimulation of alternative
S.H. Donaldson and L. Galietta



















chloride transport in the airway epithelium have
been based on the mobilization of cytosolic cal-
cium. One of the most effective ways to promote
intracellular calcium increase in airway epitheli-
al cells is by stimulation of purinergic receptors
(Mason et al. 1991). Administration of ATP or
UTP to the apical surface of the epithelium
binds to the P2Y2 nucleotide receptor and causes
a rapid increase in cytosolic free calcium con-
centration and activation of CaCCs. The result-
ing increase in chloride secretion reaches a peak
within a few seconds, though the largest part of
this lasts for only 5–15 min (Mason et al. 1991;
Galietta et al. 2002). The transient nature of this
effect is likely multifactorial. First, ATPand UTP
are rapidly hydrolyzed by ectoenzymes (Picher
et al. 2004). Second, calcium mobilization is
intrinsically transient because it is largely de-
pendent on release from intracellular calcium
stores (Mason et al. 1991). Third, desensitization
mechanisms may affect purinergic receptors
(Clarke et al. 1999) as well CaCCs themselves.
Whether these factors impact the suitability of
the purinergic receptor as a therapeutic target is
unknown.
CLINICAL STUDIES UTILIZING CaCC
PATHWAYS
To attempt to take advantage of the CaCC path-
way in CF, inhaled P2Y2 receptor agonists were
developed, thus providing an opportunity to
circumvent the CFTR-mediated chloride secre-
tory defect. This approach has the additional
potential benefits of increasing cilia beat fre-
quency and mucus secretion. While exogenous
UTP, a natural ligand for this receptor, was able
to potently stimulate mucociliary clearance in
vivo in non-CF subjects (Olivier et al. 1996; No-
one et al. 1999), it was less efficacious as a mono-
therapy (i.e., without amiloride) in CF (Bennett
et al. 1996). One logical explanation for this dis-
crepancy was that UTP is rapidly degraded by
the abundant extracellular nucleotidases found
in CF secretions.
A longer acting agonist, denufosol, was sub-
sequently synthesized to resist metabolism in the
CF airway. Following the completion of a series
of promising phase II studies (Deterding et al.
2005, 2007), two phase III studies were per-
formed. In the first (TIGER-1), 352 patients
were randomized to denufosol or placebo. As a
function of the study design, these patients were
relatively young (mean age 14.2 yr) and had
mild lung disease (baseline FEV1 92% of predict-
ed). After 24 wk of therapy, a small but statisti-
cally significant improvement in FEV1 (0.045 L;
p ¼ 0.047) was observed, without significant ef-
fects on other lung function parameters (FVC,
FEF25-75) or on the already low exacerbation
frequency. Continued improvement in the raw
FEV1 values occurred during the subsequent
24-wk open label extension period (Accurso et
al. 2011).
Following these results, a second phase III
study (TIGER-2) that included a 48-wk place-
bo-controlled treatment period and 466 pa-
tients was conducted. These patients were sim-
ilar to those studied in TIGER-1, with respect to
their mild severity of lung disease and the in-
tensity of baseline treatment regimen. Unfortu-
nately, preliminary results from this study re-
vealed no difference between denufosol- and
placebo-treated subjects in lung function im-
provement, rate of lung function change over
time, or time to first exacerbation frequency.
Why this program failed to achieve drug
registration could relate to a number of factors.
First, the adequacy of the drug itself (e.g., inad-
equate potency or durability in the CF lung) or
appropriateness of the target (e.g., receptor/
channel already occupied/activated in vivo; re-
ceptor target or signaling pathway desensitizes)
could be questioned. Second, inadequate deliv-
ery to a critical lung compartment (i.e., small
airways); or trial design issues (i.e., targeting
patients with very mild disease, where FEV1 and
exacerbation endpoints may be difficult to im-
pact) could also be problematic. Because these
issues will also impact the development of other
inhaled agents that target non-CFTR ion chan-
nels, they deserve additional scrutiny and study.
Other approaches to the treatment of CF
lung disease through modulation of ASL volume
via non-CFTR mechanisms continue to be ex-
plored. Like denufosol, Moli-1901 (duramycin)
is purported to stimulate calcium-activated
chloride channels, although the mechanism
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underlying this effect is unclear. Small studies
examining nasal potential-difference responses
and safety after short-term inhalation use have
been conducted and published (Zeitlin et al.
2004; Grasemann et al. 2007). A larger phase
IIb dose-ranging study was subsequently initi-
ated in Europe and completed in 2009, but to
date no results are available. Clearly, while tar-
geting CaCC holds promise, clinical benefits
have not yet been achieved, and more needs to




Perhaps the simplest approach to increasing ASL
volume is through the use of osmotically active
agents that draw water into the airway lumen
across the water permeable airway epithelium
(Tarran et al. 2007). HS is one currently available
osmotic “hydrator” that has been shown to
greatly reduce the frequency of pulmonary exac-
erbations and to improve lung function (Elkins
et al. 2006). The ability of HS to produce these
effects in infants and toddlers with CF is current-
ly the subject of a large study spanning North
America.
Mannitol, inhaled as a dry powder, is an al-
ternative osmotic. Dry-powder mannitol has
been shown to improve mucus rheologic prop-
erties of CF sputum (Daviskas et al. 2010) and to
stimulate the rate of mucociliary clearance in CF
and non-CF bronchiectasis patients (Daviskas
et al. 1997, 1999, 2001, 2008; Robinson et al.
1999). As might be predicted, the effect of man-
nitol on both mucociliary clearance and spi-
rometry outcomes was dose related, with doses
400 mg being most effective (Daviskas et al.
2008; Teper et al. 2011). A short-term, crossover,
phase II study in 39 CF subjects revealed a 7%
improvement from baseline in FEV1 (121 mL),
versus no change during the placebo-treatment
period. A rapid fall in lung function back to
baseline levels occurred during the 2-wk wash-
out period that followed mannitol treatment
(Jaques et al. 2008). Two large, long-term, phase
III studies have subsequently been performed in
a combined 643 patients from 11 countries. Re-
sults from these studies have not yet been pub-
lished in a peer-reviewed journal, but have been
reported at major scientific meetings (Bilton
et al. 2009). During 6 mo of double-blinded
treatment, mannitol led to an average 7.3% im-
provement in FEV1 compared to baseline ( p ,
0.001), and a similar significant improvement
when compared to placebo treatment ( p ,
0.001). In contrast to data from a small study
by Minasian et al. (2010), patients using
rhDNase with mannitol also showed lung func-
tion improvement (FEV1 5.3%; p , 0.001),
although this was numerically smaller than the
FEV1 change in those not using rhDNase (9.44%
improvement from baseline). The effect of man-
nitol on pulmonary exacerbations appears to be
smaller than that reported by Elkins et al. (2006)
in their study of HS. One possible explanation
for this difference could be the more aggressive
use of other CF medications (including inhaled
antibiotics, rhDNase, and azithromycin) during
the mannitol studies, which in turn reduced
baseline exacerbation rates and lessened the abil-
ity to see an impact on this important clinical
outcome measure. Generally speaking, the safe-
ty profile of dry-powder mannitol appears to be
good, with cough, bronchospasm, oropharyn-
geal irritation, and hemoptysis being the major
reported adverse events. Because mannitol is de-
livered as a dry powder, the requirement for a
nebulizer is obviated, and the treatment time
associated with inhaling the required 10 cap-
sules per treatment is 5 min. On the basis of
these findings, dry-powder mannitol (Bronchi-
tol; Pharmaxis) was recently approved for use in
Australia.
SUMMARY
A concerted effort to understand the epithelial
ion transport processes that govern ASL forma-
tion in normal airways, and the pathophysiolog-
ic changes that are responsible for the onset and
progression of CF lung disease, has identified
several potential therapeutic targets. A multifac-
eted strategy for finding new CF treatments that
leverages this knowledge provides the greatest
opportunity to discover beneficial, complemen-
tary treatment approaches and yield significant
S.H. Donaldson and L. Galietta



















reductions in morbidity and mortality. The
challenge that we now face, and that will contin-
ue to grow, is learning how to maximize the
benefits from multiple effective agents—rather
than the previous challenge of having little to
offer these patients.
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